<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003880.pub4" GROUP_ID="LUNGCA" ID="903102012916331448" MERGED_FROM="" MODIFIED="2010-03-15 12:15:30 +0100" MODIFIED_BY="José Angel Exposito" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;/p&gt;&lt;p&gt;Old title: Radiotherapy for malignant pleural mesothelioma-E&lt;br&gt;Old title: Radiotherapy for malignant pleural mesothelioma&lt;/p&gt;" NOTES_MODIFIED="2010-03-09 11:18:48 +0100" NOTES_MODIFIED_BY="José Angel Exposito" REVIEW_NO="ECH" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2010-03-09 11:18:48 +0100" MODIFIED_BY="José Angel Exposito">
<TITLE>Radiotherapy for malignant pleural mesothelioma</TITLE>
<CONTACT>
<PERSON ID="68A06CEF82E26AA201DBBAAB1CCA14A9" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Evelina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chapman</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>evelinachap@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiological Research Center</DEPARTMENT>
<ORGANISATION>National Academy of Medicine</ORGANISATION>
<ADDRESS_1>Carlos Gardel 768, Dpto 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>4000</ZIP>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>54 381 4281537</PHONE_1>
<PHONE_2>54 381 15887736</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-03-09 11:10:36 +0100" MODIFIED_BY="José Angel Exposito">
<PERSON ID="68A06CEF82E26AA201DBBAAB1CCA14A9" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Evelina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chapman</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>evelinachap@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiological Research Center</DEPARTMENT>
<ORGANISATION>National Academy of Medicine</ORGANISATION>
<ADDRESS_1>Carlos Gardel 768, Dpto 3</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>4000</ZIP>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1>54 381 4281537</PHONE_1>
<PHONE_2>54 381 15887736</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="68A0701C82E26AA201DBBAAB927F8596" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marcelo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>García Diéguez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gdieguez@criba.edu.ar</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Epidemiological Research Center</DEPARTMENT>
<ORGANISATION>National Academy of Medicine</ORGANISATION>
<ADDRESS_1>Pacheco de Melo 3081</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-02-02 10:22:15 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="1" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="3" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-03-09 11:18:48 +0100" MODIFIED_BY="José Angel Exposito">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-09 11:18:48 +0100" MODIFIED_BY="José Angel Exposito">
<DATE DAY="9" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Two of the previous authors were withdrawn from authors' by-line and mentioned in Acknowledgements.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-03-09 11:12:41 +0100" MODIFIED_BY="José Angel Exposito">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-03-09 11:12:41 +0100" MODIFIED_BY="José Angel Exposito">
<DATE DAY="30" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>This is an update of the 2006 review. Searches were run but no new studies were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="9" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-03-08 16:11:56 +0100" MODIFIED_BY="José Ángel Expósito Losada">
<SUMMARY MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-18 23:41:03 +0200" MODIFIED_BY="Karen Hovhannisyan">There is no evidence that radiotherapy could help to cure or to prolong the survival of patients with malignant pleural mesothelioma</TITLE>
<SUMMARY_BODY MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<P>The incidence of malignant pleural mesothelioma is increasing and is expected to peak in many developed countries in the next two decades. In 80% of the patients with malignant pleural mesothelioma there is a clear history of occupational or domestic exposure to asbestos. Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy and/or chemotherapy in curing patients or prolonging survival is uncertain. The role of radiotherapy is controversial. It has been used as a component of multimodal therapy (plus chemotherapy and/or surgery). The reviewers have not found any reports of randomised controlled trials (RCTs) that show that radiotherapy is an effective option for malignant pleural mesothelioma. There is a need for multicentre experimental studies assessing the role of radiotherapy in this disease.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Malignant pleural mesothelioma is a relatively uncommon disease, but the incidence is increasing and is expected to peak in many developed countries in the next two decades. The management of patients with malignant mesothelioma is controversial. Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy and/or chemotherapy in curing patients or prolonging survival is uncertain. The role of radiotherapy is controversial although it has been used as part of multimodal therapy. The present review will try to clarify these uncertainties.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effectiveness and safety of radiotherapy on patients with malignant pleural mesothelioma in any stage of the disease. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 4, 2008), MEDLINE (1966 to January 2009) and EMBASE (1974 to January 2009). We performed handsearches aimed at the identification of evidence by reviewing journals not indexed in databases, conference proceedings and/or scientific meetings.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled clinical trials using radiotherapy for malignant pleural mesothelioma in any stage, alone or combined with other therapies in patients of either sex and any age. We excluded studies without a control group.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>No studies fulfilled the inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>We found no reports of randomised comparisons of radiotherapy alone or combined for patients with malignant pleural mesothelioma.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<P>As radiotherapy has never been compared to chemotherapy or surgery or to best supportive care (as part of combination therapy) in a prospective, randomised trial, there are no data to support one or the other treatment as a better option for patients with malignant pleural mesothelioma. There is a need for multicentre controlled randomised trials assessing the role of radiotherapy in the radical treatment of malignant pleural mesothelioma. The studies should be limited to patients with malignant pleural mesothelioma, classified by stage, cytology and type of radiotherapy. The type of radiotherapy should be defined in advance and variables of radiotherapy dose definition and delivery should be carefully controlled.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-02 10:18:24 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Malignant mesothelioma is a tumour affecting the pleura or the peritoneum. Malignant pleural mesothelioma was described by J. Wagner (<LINK REF="REF-Wagner-1960" TYPE="REFERENCE">Wagner 1960</LINK>). The disease mainly occurs in the fifth to seventh decade of life, and in men more often than in women (3.6:1) (<LINK REF="REF-Scagliotti-2005" TYPE="REFERENCE">Scagliotti 2005</LINK>). Mesothelioma is a relatively uncommon disease, but the incidence is increasing and is expected to peak in many developed countries in the next two decades (<LINK REF="REF-Price-1997" TYPE="REFERENCE">Price 1997</LINK>; <LINK REF="REF-Peto-1999" TYPE="REFERENCE">Peto 1999</LINK>).</P>
<P>The main aetiological factor is exposure to asbestos, especially the form known as 'blue' asbestos or crocidolite. In 80% of patients with mesothelioma there is a clear history of occupational or domestic exposure to asbestos, but there is usually a long latent period between the exposure and clinical presentation (<LINK REF="REF-Bianchi-1997" TYPE="REFERENCE">Bianchi 1997</LINK>; <LINK REF="REF-Peto-1999" TYPE="REFERENCE">Peto 1999</LINK>). Another possible aetiological factor of less certain significance is the SV-40 simian virus (<LINK REF="REF-Bocchetta-2000" TYPE="REFERENCE">Bocchetta 2000</LINK>).</P>
<P>The two most common symptoms are breathlessness due to pleural effusion or diffuse pleural thickening, and chest pain, developing insidiously over several months (<LINK REF="REF-Pisani-1988" TYPE="REFERENCE">Pisani 1988</LINK>; <LINK REF="REF-Yates-1997" TYPE="REFERENCE">Yates 1997</LINK>). As the disease progresses, systemic symptoms develop with weight loss, anorexia, cough and fever, and in the terminal stages nodal and other metastases are not uncommon, although rare at presentation (<LINK REF="REF-Elmes-1976" TYPE="REFERENCE">Elmes 1976</LINK>; <LINK REF="REF-Hillerdahl-1983" TYPE="REFERENCE">Hillerdahl 1983</LINK>). Survival from the onset of symptoms is approximately one year (<LINK REF="REF-Yates-1997" TYPE="REFERENCE">Yates 1997</LINK>; <LINK REF="REF-Curran-1998" TYPE="REFERENCE">Curran 1998</LINK>). Although the clinical history and radiological findings are usually typical, a diagnosis can only be confirmed by histopathology. There are three main subtypes of malignant mesothelioma: epithelial, sarcomatoid and mixed (<LINK REF="REF-Metintas-1995" TYPE="REFERENCE">Metintas 1995</LINK>).</P>
<P>Disease stage at diagnosis is one of the most important prognostic factors. Several staging systems for this condition have been proposed, and none has been accepted universally. The oldest staging system, introduced by Butchart et al (<LINK REF="REF-Butchart-1976" TYPE="REFERENCE">Butchart 1976</LINK>), has already been abandoned due to a lack of prognostic value, in favour of TNM-based systems. The International Mesothelioma Interest Group (IMIG) proposed a TNM-based staging system based on an analysis of information about the impact of tumour and nodal status on survival (<LINK REF="REF-Rusch-1995" TYPE="REFERENCE">Rusch 1995</LINK>). Computed tomography (CT) or magnetic resonance imaging (MRI) are necessary for accurate clinical staging. Using the IMIG system, surgical staging has been shown to be superior to clinical staging (<LINK REF="REF-Heelan-1999" TYPE="REFERENCE">Heelan 1999</LINK>) and the experts recommend obtaining an earlier and reliable diagnosis by thoracoscopy except in cases of preoperative contraindication or pleural symphysis (<LINK REF="REF-Scherpereel-2009" TYPE="REFERENCE">Scherpereel 2009</LINK>). A major limitation of these staging systems is the fact that only a small minority of patients are considered suitable for surgery.</P>
<P>The management of patients with malignant mesothelioma is controversial. Very few patients are suitable for any potentially curative treatment and the effectiveness of radical therapy with surgery, radiotherapy and/or chemotherapy in curing patients or prolonging survival is uncertain. Pleurectomy and extrapleural pneumonectomy are the most widely investigated surgical procedures (<LINK REF="REF-Butchart-1976" TYPE="REFERENCE">Butchart 1976</LINK>; <LINK REF="REF-Sugarbaker-1996" TYPE="REFERENCE">Sugarbaker 1996</LINK>). Other modalities such as immunological therapy are being tested at present but the results are inconclusive. In patients with advanced disease, response rates with single or multiple chemotherapy agents rarely exceed 25%. Doxorubicin is the most widely studied drug but the overall rate of therapeutic response is still poor (<LINK REF="REF-Ong-1996" TYPE="REFERENCE">Ong 1996</LINK>; <LINK REF="REF-Ryan-1998" TYPE="REFERENCE">Ryan 1998</LINK>). New approaches are being developed for treating pleural malignant mesothelioma, such as combined pemetrexed/cisplatin chemotherapy (<LINK REF="REF-Vogelzang-2003" TYPE="REFERENCE">Vogelzang 2003</LINK>), biological agents and targeted therapies (<LINK REF="REF-Pistolesi-2004" TYPE="REFERENCE">Pistolesi 2004</LINK>).</P>
<P>The role of radiotherapy in the management is controversial. There is no evidence to suggest that radiotherapy alone affects survival although it may have a role in the palliation of pain (<LINK REF="STD-Munter-2003" TYPE="STUDY">Munter 2003</LINK>; <LINK REF="REF-Davis-1994" TYPE="REFERENCE">Davis 1994</LINK>). Because mesothelioma typically involves large areas of the pleura at diagnosis, radical, potentially curative radiotherapy is difficult to deliver to patients because of the large volumes of lung, liver, heart and spinal cord that would receive potentially toxic doses (<LINK REF="REF-Brady-1981" TYPE="REFERENCE">Brady 1981</LINK>; <LINK REF="REF-Gordon-1982" TYPE="REFERENCE">Gordon 1982</LINK>; <LINK REF="REF-Bissett-1991" TYPE="REFERENCE">Bissett 1991</LINK>; <LINK REF="REF-Hakkinen-1996" TYPE="REFERENCE">Hakkinen 1996</LINK>). Also, there have been described cases of fatal pneumonitis in some patients undergoing radiotherapy (<LINK REF="REF-Allen-2006" TYPE="REFERENCE">Allen 2006</LINK>).</P>
<P>Radiotherapy has been used as a component of multimodal therapy. Following radical surgery, radiotherapy may be effective in reducing local recurrence of the tumour and improving overall survival (<LINK REF="STD-Rusch-2001" TYPE="STUDY">Rusch 2001</LINK>). Some authors have suggested that radiotherapy plus chemotherapy as an adjuvant to surgery results in a 22% survival at five years (<LINK REF="REF-Sugarbaker-1996" TYPE="REFERENCE">Sugarbaker 1996</LINK>; <LINK REF="STD-Maggi-2001" TYPE="STUDY">Maggi 2001</LINK>). The effectiveness of radiotherapy alone or in combination for curative or palliative purposes remains uncertain and the most appropriate and effective dose and techniques are unclear (<LINK REF="STD-Law-1984" TYPE="STUDY">Law 1984</LINK>; <LINK REF="REF-Alberts-1988" TYPE="REFERENCE">Alberts 1988</LINK>; <LINK REF="REF-Baldini-2004" TYPE="REFERENCE">Baldini 2004</LINK>).</P>
<P>The present review will try to clarify these uncertainties.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effectiveness and safety of radiotherapy on patients with malignant pleural mesothelioma in any stage of the disease. </P>
</OBJECTIVES>
<METHODS MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled clinical trials using radiotherapy for malignant pleural mesothelioma in any stage, alone or combined with other therapies. We excluded studies without a control group and studies on prophylactic treatment to incision sites.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients of either sex and any age with a diagnosis of malignant pleural mesothelioma, confirmed by histopathology, of any stage at presentation. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<P>a) Megavoltage external beam radiotherapy, either conventional, conformal or intensity modulated.<BR/>b) Kilovoltage radiotherapy<BR/>c) Brachytherapy with interstitial implants or non-sealed sources.</P>
<P>Both curative and palliative radiotherapy were considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was overall survival (defined from the time of randomisation to the time of death due to any cause).</P>
<P>We also considered the following additional outcomes for inclusion:</P>
<P>1) Studies with curative intent:<BR/>a. Progression-free survival<BR/>b. Symptom relief, particularly of breathlessness and pain.<BR/>c. Objective tumour response<BR/>d. Radiation adverse events</P>
<P>2) Studies with palliative intent:<BR/>a. Symptom relief, particularly of breathlessness and pain.<BR/>b. Radiation adverse events</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted electronic and handsearches.</P>
<P>1. Electronic search: we searched all randomised controlled clinical trials in electronic databases such as the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library</I> Issue 4, 2008), MEDLINE (1966 to January 2009) and EMBASE (1974 to January 2009). Searches were designed according to the recommendations by the Cochrane Collaboration (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and run by the Trials Search Co-ordinator.</P>
<P>2. Handsearching was aimed at the identification of evidence by reviewing journals not indexed in databases, proceedings of conferences and/or scientific meetings. We located other studies by searching in the literature references identified by the first search of the review.</P>
<P>3. We contacted other researchers, scientific societies and experts.</P>
<P>SEARCH STRATEGY<BR/>#1 (((tumour* AND pleura) OR (tumour* AND peritoneum) OR (tumour* AND pericardium)) AND mesothelioma[tw]) OR ((pleura* AND neoplasm*) AND mesothelioma[tw]) OR (pleural neoplasm[mh] AND mesothelioma[tw]) OR (mesothelioma[mh] OR mesothelioma*[tw])<BR/>#2 (radiotherapy[mh] OR radiation oncology[mh] OR (thoracic* AND radiotherap*) OR (thoracic* AND radiation*) OR (radiation[tw] AND therap*[tw]))<BR/>#3 1 AND 2</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>The search did not identify any studies that fulfilled the inclusion criteria.<BR/>
<B>
<I>
<BR/>
</I>
</B>Methods that would be applied if trials were included in a future update of the review:</P>
<P>All studies would be selected and assessed independently by two qualified reviewers. Included studies would be assessed in accordance with The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<P>For each study, the following should be considered:</P>
<P>Selection bias: systematic differences between baseline characteristics of the comparison groups.</P>
<P>- Sequence generation: a description for allocating interventions to participants based on a random process.</P>
<P>- Allocation concealment: a description of any method to secure implementation of the random assignments to prevent that those allocations could have been foreseen.</P>
<P>Performance bias: systematic differences between groups in the care provided or in other factors different from the intervention.</P>
<P>- Blinding of participants, personnel and outcome assessors: a description of measures used to blind study participants and personnel for knowledge of which intervention a participant received. Description of any evaluation of effective blinding should be considered. Blinding should be considered important for the outcomes of symptom relief, particularly of breathlessness and pain, tumour response and adverse events.</P>
<P>Attrition bias: systematic differences between groups in withdrawals from the study.</P>
<P>- Incomplete outcome data: a description of the level of completeness of each outcome, including attrition and exclusions. Number of randomised patients in each group and number of evaluated patients with reasons for attrition or exclusion reported.</P>
<P>For each domain, two authors independently should judge the of risk of bias in accordance with the following classification: Yes, for low risk of bias; No, for high risk of bias; Unclear, for insufficient information reported.</P>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>To ensure validity, two qualified team members would extract all data independently, any difference would be resolved by a third team member.<BR/>We would contact authors of the studies for further information. We would enter details of studies meeting the selection criteria using ProCite.<BR/>We would analyse heterogeneity among studies using the Chi<SUP>2</SUP> test, and P &lt; 0.01 would indicate heterogeneity. If we identified heterogeneity, we would conduct a further analysis to identify possible causes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical analysis</HEADING>
<P>For normally distributed continuous outcomes, we would calculate mean differences. For binary outcomes, where sufficient data were available, we would present relative treatment effects in the form of odds ratios (OR) and 95% confidence intervals. We would perform the analysis using RevMan 5.0. We would perform a sensitivity analysis and we would measure publication bias depending on how much information was available.</P>
<P>For time to event outcomes we would present log hazard ratios (log HR). We would pool data only if this made sense clinically. If estimates of log HR and its variance were not quoted directly in trial reports, we would extract alternative aggregate data (e.g., log rank test P value) in order to calculate pooled HR estimates.</P>
<P>Another alternative would be the analysis for different follow-up periods using different time points as part of the outcome, which may approximate a survival analysis (survival). We would analyse adverse events as the number of patients experiencing each of the adverse events described in the studies.</P>
<P>We would also perform intention-to-treat analysis.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>The initial electronic search found 263 references (123 in MEDLINE, 22 in CENTRAL and 118 in EMBASE), 225 studies were selected for further evaluation (123 in MEDLINE , 18 in CENTRAL and 84 in EMBASE). A second review cut down to 22 the number of studies finally evaluated.</P>
<P>The new electronic search up to January 2009, found 171 references (37 in MEDLINE and 134 in EMBASE). Seven studies were finally evaluated for possible inclusion but did not fulfill the criteria.<B> </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prophylactic treatment of incision sites studies</HEADING>
<P>Four studies (<LINK REF="STD-Boutin-1995" TYPE="STUDY">Boutin 1995</LINK>; <LINK REF="STD-Ratto-1999" TYPE="STUDY">Ratto 1999</LINK>; <LINK REF="STD-Bydder-2004" TYPE="STUDY">Bydder 2004</LINK>; <LINK REF="STD-Cellerin-2004" TYPE="STUDY">Cellerin 2004</LINK>) were excluded because they used radiotherapy (RT) for the prophylactic treatment of incision sites after invasive diagnostic or therapeutic procedures to prevent chest wall implantation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bimodal therapy studies</HEADING>
<P>Eleven studies on bimodal therapy were evaluated (<LINK REF="STD-Law-1984" TYPE="STUDY">Law 1984</LINK>; <LINK REF="STD-Sauter-1995" TYPE="STUDY">Sauter 1995</LINK>; <LINK REF="STD-Linden-1996" TYPE="STUDY">Linden 1996</LINK>; <LINK REF="STD-Herscher-1998" TYPE="STUDY">Herscher 1998</LINK>; <LINK REF="STD-Rusch-2001" TYPE="STUDY">Rusch 2001</LINK>; <LINK REF="STD-Ahamad-2003" TYPE="STUDY">Ahamad 2003</LINK>; <LINK REF="STD-Munter-2003" TYPE="STUDY">Munter 2003</LINK>; <LINK REF="STD-Yajnik-2003" TYPE="STUDY">Yajnik 2003</LINK>; <LINK REF="STD-Halstead-2004" TYPE="STUDY">Halstead 2004</LINK>; <LINK REF="STD-Rosenzweig-2005" TYPE="STUDY">Rosenzweig 2005</LINK>; <LINK REF="STD-Allen-2007" TYPE="STUDY">Allen 2007</LINK>). All were case series without control group treated with different modalities of radiotherapy, usually after surgery.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Multimodal therapy studies</HEADING>
<P>Thirteen studies on multimodal therapy were evaluated (<LINK REF="STD-Calavrezos-1988" TYPE="STUDY">Calavrezos 1988</LINK>; <LINK REF="STD-Maasilta-1991" TYPE="STUDY">Maasilta 1991</LINK>; <LINK REF="STD-Mattson-1992" TYPE="STUDY">Mattson 1992</LINK>; <LINK REF="REF-Sugarbaker-1996" TYPE="REFERENCE">Sugarbaker 1996</LINK>; <LINK REF="STD-Holsti-1997" TYPE="STUDY">Holsti 1997</LINK>; <LINK REF="STD-Sugarbaker-1999" TYPE="STUDY">Sugarbaker 1999</LINK>; <LINK REF="STD-Maggi-2001" TYPE="STUDY">Maggi 2001</LINK>; <LINK REF="STD-Lee-2002" TYPE="STUDY">Lee 2002</LINK>; <LINK REF="STD-Weder-2004" TYPE="STUDY">Weder 2004</LINK>; <LINK REF="STD-Flores-2006" TYPE="STUDY">Flores 2006</LINK>; <LINK REF="STD-Pagan-2006" TYPE="STUDY">Pagan 2006</LINK>; <LINK REF="STD-Lucchi-2007" TYPE="STUDY">Lucchi 2007</LINK>; <LINK REF="STD-Rea-2007" TYPE="STUDY">Rea 2007</LINK>). All were case series without control group treated with surgery, radiotherapy and chemotherapy, all with different modalities.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-01-18 09:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>No studies fulfilled the inclusion criteria. No studies were excluded because of poor methodology.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>To date we have not found any reports of randomised comparisons of radiotherapy alone or combined for patients with malignant pleural mesothelioma.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-02-02 10:18:24 +0100" MODIFIED_BY="[Empty name]">
<P>The rapidly increasing incidence of malignant pleural mesothelioma underlines the urgent need to achieve a consensus about the management of this tumour. Despite malignant pleural mesothelioma being a relatively rare disease, the incidence is increasing, and in the identified studies, the rates of median survival varied between about six months and two years but these results came from studies of low methodological quality. We have found no clinical trials involving radiotherapy as a treatment for malignant pleural mesothelioma. Nevertheless, survival of malignant pleural mesothelioma has improved with the treatment with pemetrexed in addition to cisplatin (<LINK REF="REF-Vogelzang-2003" TYPE="REFERENCE">Vogelzang 2003</LINK>).  </P>
<P>There has been no consensus in the literature to guide the most appropriate management of patients with malignant pleural mesothelioma. This has been primarily due to a lack of convincing data identifying any single radiotherapy treatment modality or combination that might offer a clinically meaningful and significant improvement in survival or quality of life over best supportive care. Adverse effects and serious complications (sometimes fatal) should also be evaluated properly in randomised studies.</P>
<P>We obtained some evidence from the literature for using radiotherapy to treat incision sites after invasive diagnostic or therapeutic studies to prevent chest wall implantation, but this issue is outside the scope of this review.</P>
<P>Finally, as we had previously agreed not to accept non-randomised studies, all the identified papers had to be excluded because all were retrospective or prospective series of cases. All provided non-randomised comparisons that were considered unacceptable for supporting an evidence-based recommendation. In the absence of direct evidence on the effectiveness and safety of radiotherapy compared to other therapies for malignant pleural mesothelioma, we can only conclude that further specific research by prospective randomised trials is needed.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-02-02 10:17:25 +0100" MODIFIED_BY="[Empty name]">
<P>As radiotherapy has never been compared to chemotherapy or surgery or to best supportive care (as part of combined therapy) in a prospective, randomised trial, there are no data to support one or other treatment as a better option for patients with malignant pleural mesothelioma, and there is insufficient information about its safety.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-01-05 01:01:24 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for multicentre randomised controlled trials assessing the role of radiotherapy in the treatment of malignant pleural mesothelioma as well as adverse effects. The studies should be limited to patients with malignant pleural mesothelioma, classified by stages, cytology and type of radiotherapy. The type of radiotherapy should be defined in advance and variables of radiotherapy dose definition and delivery should be carefully controlled.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-03-08 16:11:56 +0100" MODIFIED_BY="José Ángel Expósito Losada">
<P>Authors would like to thank Graciela Berenstein and Zulma Ortiz, co-authors of the previous version of the review.<BR/>Thanks to Sera Tort and José Expósito for their methodological support and to Ivan Solà for the search strategy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-09-30 00:12:04 +0200" MODIFIED_BY="[Empty name]">
<P>GB and ZO contributed to the protocol development and provided methodological support. MGD contributed to review and selection of studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-02 10:19:40 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-02-02 10:19:40 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-01-05 01:35:34 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2010-02-02 10:19:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahamad-2003" MODIFIED="2009-09-29 23:20:21 +0200" MODIFIED_BY="[Empty name]" NAME="Ahamad 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-29 23:20:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahamad A, Stevens CW, Smythe WR, Vaporciyan AA, Komaki R, Kelly JF et al</AU>
<TI>Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2003</YR>
<VL>55</VL>
<NO>3</NO>
<PG>768-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-09-29 11:28:57 +0200" MODIFIED_BY="José Ángel Expósito Losada"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2007" MODIFIED="2009-09-29 22:21:56 +0200" MODIFIED_BY="[Empty name]" NAME="Allen 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-09-29 22:21:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen AM, Schofield D, Hacker F, Court LE, Czerminska M</AU>
<TI>Restricted field IMRT dramatically enhances IMRT planning for mesothelioma</TI>
<SO>International Journal of Radiation Oncology</SO>
<YR>2007</YR>
<VL>69(5)</VL>
<PG>1587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boutin-1995" MODIFIED="2009-09-29 11:30:25 +0200" MODIFIED_BY="José Ángel Expósito Losada" NAME="Boutin 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-29 11:30:25 +0200" MODIFIED_BY="José Ángel Expósito Losada" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boutin C, Rey F, Viallat JR</AU>
<TI>Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>3</NO>
<PG>754-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bydder-2004" MODIFIED="2010-01-18 09:58:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bydder 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-18 09:58:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, Musk AW. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004 Jul 5;91(1):9-10.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 09:58:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y et al</AU>
<TI>A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>1</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calavrezos-1988" MODIFIED="2010-01-18 09:59:10 +0100" MODIFIED_BY="[Empty name]" NAME="Calavrezos 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-01-18 09:59:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr. 1988 Jul 15;66(14):607-13.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 09:59:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H et al</AU>
<TI>Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985</TI>
<SO>Wien Klin Wochenschr</SO>
<YR>1988</YR>
<VL>66</VL>
<NO>14</NO>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cellerin-2004" MODIFIED="2009-09-29 23:28:57 +0200" MODIFIED_BY="[Empty name]" NAME="Cellerin 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-29 23:28:57 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Cellerin L, Garry P, Mahe MA, Chailleux E. Malignant pleural mesothelioma: radiotherapy for the prevention of seeding Nodules. Rev Mal Respir. 2004 Feb;21(1):53-8.&lt;/p&gt;" NOTES_MODIFIED="2009-09-29 23:28:57 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cellerin L, Garry P, Mahe MA, Chailleux E</AU>
<TI>Malignant pleural mesothelioma: radiotherapy for the prevention of seeding Nodules</TI>
<SO>Revue des maladies respiratoires</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores-2006" MODIFIED="2010-01-05 09:35:32 +0100" MODIFIED_BY="[Empty name]" NAME="Flores 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-05 09:35:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R et al</AU>
<TI>Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2006</YR>
<VL>1(4)</VL>
<PG>289-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halstead-2004" MODIFIED="2010-01-18 09:59:27 +0100" MODIFIED_BY="[Empty name]" NAME="Halstead 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-18 09:59:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard M, Ritchie AJ</AU>
<TI>Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2005</YR>
<VL>31(3)</VL>
<PG>314-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herscher-1998" MODIFIED="2010-02-02 10:19:40 +0100" MODIFIED_BY="[Empty name]" NAME="Herscher 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-02-02 10:19:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, Liebmann J. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol. 1998 Feb;16(2):635-41.&lt;/p&gt;" NOTES_MODIFIED="2010-02-02 10:19:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B et al</AU>
<TI>Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>2</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holsti-1997" MODIFIED="2010-01-16 20:59:48 +0100" MODIFIED_BY="[Empty name]" NAME="Holsti 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-16 20:59:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Holsti, L R.Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol 1997;36(4):397-405.&lt;/p&gt;" NOTES_MODIFIED="2010-01-16 20:59:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holsti LR</AU>
<TI>Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment</TI>
<SO>Acta Oncologica</SO>
<YR>1997</YR>
<VL>36</VL>
<NO>4</NO>
<PG>397-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaukel-1992" NAME="Kaukel 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kaukel E, Koschel G, Schulz P Konservative, palliative Therapie des malignen Pleuramesothelioms. Langenbecks Archiv fur Chirurgie Supplement Kongressband Deutsche Gesellschaft fur Chirurgie Kongress. 1992; 180-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaukel E, Koschel G, Schulz P</AU>
<TI>Conservative, palliative therapy of malignant pleural mesothelioma</TI>
<TO>Konservative, palliative Therapie des malignen Pleuramesothelioms</TO>
<SO>Langenbecks Archiv fur Chirurgie Supplement Kongressband Deutsche Gesellschaft fur Chirurgie Kongress</SO>
<YR>1992</YR>
<PG>180-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Law-1984" MODIFIED="2009-09-29 23:31:14 +0200" MODIFIED_BY="[Empty name]" NAME="Law 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-09-29 23:31:14 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984 Apr;39(4):255-9.&lt;/p&gt;" NOTES_MODIFIED="2009-09-29 23:31:14 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M</AU>
<TI>Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients</TI>
<SO>Thorax</SO>
<YR>1984</YR>
<VL>39</VL>
<NO>4</NO>
<PG>255-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2002" MODIFIED="2010-01-18 10:04:14 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-18 10:04:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee, TT</AU>
<TI>Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2002</YR>
<VL>124</VL>
<NO>6</NO>
<PG>1183-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linden-1996" MODIFIED="2010-01-16 21:01:11 +0100" MODIFIED_BY="[Empty name]" NAME="Linden 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-16 21:01:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J. 1996 Dec; 9(12):2565-72.&lt;/p&gt;" NOTES_MODIFIED="2010-01-16 21:01:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB</AU>
<TI>Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a non randomized phase II study</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>12</NO>
<PG>2565-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucchi-2007" MODIFIED="2010-01-18 10:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lucchi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-18 10:05:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucchi M, Chella A, Melfi F et al</AU>
<TI>Four-modality therapy in malignant pleural mesothelioma: A phase II study</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2007</YR>
<VL>2(3)</VL>
<PG>237-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maasilta-1991" MODIFIED="2010-01-18 10:07:46 +0100" MODIFIED_BY="[Empty name]" NAME="Maasilta 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-01-18 10:07:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):433-8.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 10:07:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maasilta P</AU>
<TI>Deterioration in lung function following hemithorax irradiation for pleural mesothelioma</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>3</NO>
<PG>433-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maggi-2001" MODIFIED="2010-01-18 10:00:16 +0100" MODIFIED_BY="[Empty name]" NAME="Maggi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-18 10:00:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maggi G</AU>
<TI>Trimodality management of malignant pleural mesothelioma</TI>
<SO>European Journal of Cardio-thoracic Surgery</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>3</NO>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-1992" MODIFIED="2010-01-18 10:08:46 +0100" MODIFIED_BY="[Empty name]" NAME="Mattson 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-01-18 10:08:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mattson K, Holsti LR, Tammilehto L, Maasilta P, Pyrh&amp;#246;nen S, M&amp;#228;ntyl&amp;#228; M, Kajanti M, Salminen US, Rautonen J, Kivisaari L. Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. International journal of radiation oncology, biology, physics. 1992;24 (4): 643-50.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 10:08:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattson K, Holsti LR, Tammilehto L, Maasilta P, Pyrhönen S, Mäntylä M et al</AU>
<TI>Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>4</NO>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munter-2003" MODIFIED="2010-01-18 10:00:02 +0100" MODIFIED_BY="[Empty name]" NAME="Munter 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-18 10:00:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munter MW</AU>
<TI>Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results</TI>
<SO>Strahlentherapie und Onkologie</SO>
<YR>2003</YR>
<VL>179</VL>
<NO>8</NO>
<PG>535-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagan-2006" MODIFIED="2009-09-29 22:36:05 +0200" MODIFIED_BY="[Empty name]" NAME="Pagan 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-29 22:36:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagan V, Ceron L, Paccagnella A, Pizzi G</AU>
<TI>5-year prospective results of trimodality treatment for malignant pleural mesothelioma</TI>
<SO>Journal of Cardiovascular Surgery (Torino)</SO>
<YR>2006</YR>
<VL>47(5)</VL>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratto-1999" MODIFIED="2010-01-18 10:00:35 +0100" MODIFIED_BY="[Empty name]" NAME="Ratto 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-18 10:00:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ratto-G-B, Civalleri-D, Esposito-M, Spessa-E, Alloisio-A, De-Cian-F, Vannozzi-M-O. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study. Journal of Thoracic and Cardiovascular Surgery 1999; 117 (4):759-765.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 10:00:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO</AU>
<TI>Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>4</NO>
<PG>759-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rea-2007" MODIFIED="2010-01-18 10:03:19 +0100" MODIFIED_BY="[Empty name]" NAME="Rea 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-18 10:03:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L et al</AU>
<TI>Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and  results</TI>
<SO>Lung Cancer</SO>
<YR>2007</YR>
<VL>57(1)</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenzweig-2005" MODIFIED="2010-01-18 10:00:48 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenzweig 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-18 10:00:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenzweig KE, Fox JL, Zelefsky MJ, Raben A, Harrison LB, Rusch VW</AU>
<TI>A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma</TI>
<SO>Brachytherapy</SO>
<YR>2005</YR>
<VL>4(1)</VL>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rusch-2001" MODIFIED="2010-01-18 10:03:30 +0100" MODIFIED_BY="[Empty name]" NAME="Rusch 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-18 10:03:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS,Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 10:03:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L et al</AU>
<TI>A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2001</YR>
<VL>122</VL>
<NO>4</NO>
<PG>788-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sauter-1995" MODIFIED="2010-01-16 21:06:44 +0100" MODIFIED_BY="[Empty name]" NAME="Sauter 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-01-16 21:06:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM. Optimal management of malignant mesothelioma after subtotal pleurectomy:revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol. 1995 Oct;60(2):100-5.&lt;/p&gt;" NOTES_MODIFIED="2010-01-16 21:06:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM</AU>
<TI>Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>1995</YR>
<VL>60</VL>
<NO>2</NO>
<PG>100-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugarbaker--1996" MODIFIED="2010-01-18 10:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Sugarbaker  1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-18 10:03:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugarbaker DJ</AU>
<TI>Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients</TI>
<SO>Annals of Surgery</SO>
<YR>1996</YR>
<VL>224</VL>
<NO>3</NO>
<PG>288-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugarbaker-1999" MODIFIED="2010-01-18 10:03:48 +0100" MODIFIED_BY="[Empty name]" NAME="Sugarbaker 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-18 10:03:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugarbaker DJ</AU>
<TI>Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients</TI>
<SO>The Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>1</NO>
<PG>54-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weder-2004" MODIFIED="2009-09-29 23:35:37 +0200" MODIFIED_BY="[Empty name]" NAME="Weder 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-29 23:35:37 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Weder W . Neoadjuvant chemotherapy followed by extrapleural neumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004 Sep 1;22(17):3451-7.&lt;/p&gt;" NOTES_MODIFIED="2009-09-29 23:35:37 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weder W</AU>
<TI>Neoadjuvant chemotherapy followed by extrapleural neumonectomy in malignant pleural mesothelioma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>17</NO>
<PG>3451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yajnik-2003" MODIFIED="2010-01-18 09:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Yajnik 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-18 09:53:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Yajnik, Santosh. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. - Int J Radiat Oncol Biol Phys 2003 Aug 1;56(5):1319-26.&lt;/p&gt;" NOTES_MODIFIED="2010-01-18 09:53:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yajnik, S</AU>
<TI>Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>5</NO>
<PG>1319-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-01-18 10:11:31 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-01-18 10:11:31 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alberts-1988" MODIFIED="2010-01-18 09:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="Alberts 1988" TYPE="JOURNAL_ARTICLE">
<AU>Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA</AU>
<TI>Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<PG>527-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2006" MODIFIED="2010-01-18 10:09:45 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Allen AM, Czerminska M, Janne PA et al</AU>
<TI>Fatal pneumonitis associated with intensity modulated radiation therapy for mesothelioma</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2006</YR>
<VL>65</VL>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baldini-2004" MODIFIED="2010-01-18 09:54:44 +0100" MODIFIED_BY="[Empty name]" NAME="Baldini 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baldini EH</AU>
<TI>External beam radiation therapy for the treatment of pleural mesothelioma</TI>
<SO>Thoracic Surgery Clinics</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>4</NO>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bianchi-1997" MODIFIED="2010-01-18 09:54:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bianchi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C</AU>
<TI>Latency periods in asbestos-related mesothelioma of the pleura</TI>
<SO>European journal of cancer prevention</SO>
<YR>1997</YR>
<VL>6</VL>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bissett-1991" MODIFIED="2010-01-18 09:55:10 +0100" MODIFIED_BY="[Empty name]" NAME="Bissett 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bissett D, Macbeth FR, Cram I</AU>
<TI>The Role of Palliative Radiotherapy in Malignant Mesothelioma</TI>
<SO>Clinical Oncology</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>315-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bocchetta-2000" MODIFIED="2010-01-18 09:55:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bocchetta 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bocchetta M, Di Resta I, Powers A, Fresno R, Tosolini A, Testa JR et al</AU>
<TI>Human mesothelioma cells are unusually susceptible to simian virus 40-mediated transformation and asbestos carcinogenity</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2000</YR>
<VL>97</VL>
<PG>10214-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brady-1981" MODIFIED="2010-01-18 09:55:29 +0100" MODIFIED_BY="[Empty name]" NAME="Brady 1981" TYPE="JOURNAL_ARTICLE">
<AU>Brady LW</AU>
<TI>Mesothelioma, the role for radiation therapy</TI>
<SO>Seminars in Oncology</SO>
<YR>1981</YR>
<VL>8</VL>
<PG>329-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Butchart-1976" MODIFIED="2010-01-18 09:55:48 +0100" MODIFIED_BY="[Empty name]" NAME="Butchart 1976" TYPE="JOURNAL_ARTICLE">
<AU>Butchart EG, Ashcroft T, Barnsley WC, Holden MP</AU>
<TI>Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients</TI>
<SO>Thorax</SO>
<YR>1976</YR>
<VL>31</VL>
<PG>15-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curran-1998" MODIFIED="2010-01-18 09:55:52 +0100" MODIFIED_BY="[Empty name]" NAME="Curran 1998" TYPE="JOURNAL_ARTICLE">
<AU>Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G</AU>
<TI>Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>145-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1994" MODIFIED="2010-01-18 09:55:54 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 1994" TYPE="JOURNAL_ARTICLE">
<AU>Davis SR, Tan L, Ball DL</AU>
<TI>Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation</TI>
<SO>Australasian radiology</SO>
<YR>1994</YR>
<VL>38</VL>
<PG>212-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elmes-1976" MODIFIED="2010-01-18 09:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Elmes 1976" TYPE="JOURNAL_ARTICLE">
<AU>Elmes PC, Simpson MJC</AU>
<TI>The clinical aspects of mesothelioma</TI>
<SO>The Quarterly Journal of Medicine</SO>
<YR>1976</YR>
<VL>45</VL>
<PG>427-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-1982" MODIFIED="2010-01-18 10:10:14 +0100" MODIFIED_BY="[Empty name]" NAME="Gordon 1982" TYPE="JOURNAL_ARTICLE">
<AU>Gordon W Jr, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT</AU>
<TI>Radiation therapy in the management of patients with mesothelioma</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hakkinen-1996" MODIFIED="2010-01-18 09:56:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hakkinen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hakkinen AM, Laasonen A, Linnainmaa K, Mattson K, Pyrhonen S</AU>
<TI>Radiosensitivity of mesothelioma cell lines</TI>
<SO>Acta Oncologica</SO>
<YR>1996</YR>
<VL>35</VL>
<PG>451-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heelan-1999" MODIFIED="2010-01-18 09:56:08 +0100" MODIFIED_BY="[Empty name]" NAME="Heelan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C</AU>
<TI>Staging of malignant pleural mesothelioma: comparison of CT and MR imaging</TI>
<SO>American Journal of Roentgenology</SO>
<YR>1999</YR>
<VL>172</VL>
<PG>1039-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-01-05 10:08:52 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.0.1 [updated September 2008]</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillerdahl-1983" MODIFIED="2009-09-30 07:10:47 +0200" MODIFIED_BY="[Empty name]" NAME="Hillerdahl 1983" TYPE="JOURNAL_ARTICLE">
<AU>Hillerdahl G</AU>
<TI>Malignant mesothelioma: review of 4710 published cases</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1983</YR>
<VL>77</VL>
<PG>321-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metintas-1995" MODIFIED="2010-01-18 09:56:16 +0100" MODIFIED_BY="[Empty name]" NAME="Metintas 1995" TYPE="JOURNAL_ARTICLE">
<AU>Metintas M, Özdemir N, Isikoy S, Kaya T, Ekici M, Erginel S et al</AU>
<TI>CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma</TI>
<SO>Journal of Computer Assisted Tomography</SO>
<YR>1995</YR>
<VL>19</VL>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ong-1996" MODIFIED="2009-09-30 07:11:24 +0200" MODIFIED_BY="[Empty name]" NAME="Ong 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ong ST, Vogelzang NG</AU>
<TI>Chemotherapy in malignant pleural mesothelioma. A review</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>1007-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peto-1999" MODIFIED="2010-01-18 09:56:18 +0100" MODIFIED_BY="[Empty name]" NAME="Peto 1999" TYPE="JOURNAL_ARTICLE">
<AU>Peto J, Decarli A, La Vecchia C, Levi F, Negri E</AU>
<TI>The European mesothelioma epidemic</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>79</VL>
<PG>666-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pisani-1988" MODIFIED="2010-01-18 10:11:31 +0100" MODIFIED_BY="[Empty name]" NAME="Pisani 1988" TYPE="JOURNAL_ARTICLE">
<AU>Pisani RJ, Colby TV, Williams DE</AU>
<TI>Malignant mesothelioma of the pleura</TI>
<SO>Mayo Clinic Proceedings.</SO>
<YR>1988</YR>
<VL>63</VL>
<PG>1234-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pistolesi-2004" MODIFIED="2010-01-18 09:56:22 +0100" MODIFIED_BY="[Empty name]" NAME="Pistolesi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pistolesi M, Rusthoven J</AU>
<TI>Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4</NO>
<PG>1318-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-1997" MODIFIED="2010-01-18 09:57:17 +0100" MODIFIED_BY="[Empty name]" NAME="Price 1997" TYPE="JOURNAL_ARTICLE">
<AU>Price B</AU>
<TI>Analysis of current trends in United States mesothelioma incidence</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1997</YR>
<VL>145</VL>
<PG>211-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rusch-1995" MODIFIED="2010-01-18 09:57:22 +0100" MODIFIED_BY="[Empty name]" NAME="Rusch 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rusch VW</AU>
<TI>A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<NO>4</NO>
<PG>1122-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ryan-1998" MODIFIED="2010-01-18 09:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="Ryan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ryan CW, Herndon J, Vogelzang NG</AU>
<TI>A review of chemotherapy trials for malignant mesothelioma</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>113</VL>
<NO>Suppl 1</NO>
<PG>66S-73S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scagliotti-2005" MODIFIED="2010-01-18 09:57:43 +0100" MODIFIED_BY="[Empty name]" NAME="Scagliotti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Scagliotti GV, Novello S</AU>
<TI>State of the art in mesothelioma</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>Supplement 2</NO>
<PG>ii240-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scherpereel-2009" MODIFIED="2010-01-05 09:39:54 +0100" MODIFIED_BY="[Empty name]" NAME="Scherpereel 2009" TYPE="JOURNAL_ARTICLE">
<AU>Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P et al</AU>
<TI>Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of Malignant Pleural Mesothelioma</TI>
<SO>European Respiratory Journal</SO>
<YR>2009, Aug 28</YR>
<IDENTIFIERS MODIFIED="2010-01-05 09:39:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-05 09:39:17 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="PMID- 19717482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sugarbaker-1996" MODIFIED="2010-01-18 09:57:56 +0100" MODIFIED_BY="[Empty name]" NAME="Sugarbaker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH Jr, Healy-Baldini E, DeCamp MM Jr et al</AU>
<TI>Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients</TI>
<SO>Annals of Surgery</SO>
<YR>1996</YR>
<VL>224</VL>
<PG>288-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogelzang-2003" MODIFIED="2010-01-18 09:57:59 +0100" MODIFIED_BY="[Empty name]" NAME="Vogelzang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al</AU>
<TI>Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>14</NO>
<PG>2636-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-1960" MODIFIED="2010-01-18 10:11:09 +0100" MODIFIED_BY="[Empty name]" NAME="Wagner 1960" TYPE="JOURNAL_ARTICLE">
<AU>Wagner JC, Sleggs EA, Marchand P</AU>
<TI>Diffuse pleural mesothelioma and asbestos in the North Western Cape Province</TI>
<SO>British Journal of Industrial Medicine</SO>
<YR>1960</YR>
<VL>17</VL>
<PG>260-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yates-1997" MODIFIED="2010-01-18 09:58:04 +0100" MODIFIED_BY="[Empty name]" NAME="Yates 1997" TYPE="JOURNAL_ARTICLE">
<AU>Yates DH, Corrin B, Stidolph PN, Browne K</AU>
<TI>Malignant mesothelioma in south east England: clinicopathological experience of 272 cases</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-09-30 10:10:43 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chapman-2006" MODIFIED="2009-09-30 10:10:42 +0200" MODIFIED_BY="[Empty name]" NAME="Chapman 2006" TYPE="COCHRANE_REVIEW">
<AU>Chapman E, García Diéguez M, Berenstein G, Ortiz Z</AU>
<TI>Radiotherapy for malignant pleural mesothelioma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-09-30 10:10:42 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-30 10:10:42 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD003880. DOI: 10.1002/14651858.CD003880.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-01-05 01:35:34 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-01-05 01:35:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-09-30 07:03:02 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ahamad-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-29 23:13:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-29 23:13:39 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boutin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Preventive radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bydder-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Preventive radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calavrezos-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cellerin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Preventive radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-30 07:02:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-30 07:02:27 +0200" MODIFIED_BY="[Empty name]">
<P>Non-controlled phase II trial of chemotherapy and radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-30 07:02:31 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halstead-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-30 07:02:31 +0200" MODIFIED_BY="[Empty name]">
<P>Non-controlled case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herscher-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holsti-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaukel-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Law-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linden-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-30 07:02:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucchi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-30 07:02:53 +0200" MODIFIED_BY="[Empty name]">
<P>Non-controlled phase II trial of chemotherapy and radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maasilta-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maggi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattson-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Munter-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-29 23:16:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pagan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-29 23:16:48 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-30 07:03:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratto-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-30 07:03:02 +0200" MODIFIED_BY="[Empty name]">
<P>Preventive radiotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-29 23:16:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rea-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-29 23:16:27 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-29 23:16:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenzweig-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-29 23:16:39 +0200" MODIFIED_BY="[Empty name]">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rusch-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sauter-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sugarbaker--1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sugarbaker-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weder-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yajnik-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-01-05 01:35:34 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-01-05 01:35:34 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>